Allarity Therapeutics
Clinical trials sponsored by Allarity Therapeutics, explained in plain language.
Develops personalized cancer therapies using drug response prediction.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New test could match ovarian cancer patients to the right drug Results expected Jun 2027 (estimated)
-
Experimental cancer combo tested in tiny, terminated trial
Disease control Stopped earlyThis early-stage trial tested a new drug called 2X-121, alone and combined with another drug called dovitinib, in 14 people with advanced solid tumors. The goal was to find the safest dose and check for side effects. The study was terminated early, so results are limited and no c…
Phase 1 • Sponsor: Allarity Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Experimental chemo drug tested for advanced breast cancer
Disease control Stopped earlyThis phase 2 trial tested the chemotherapy drug ixabepilone in 13 patients with metastatic breast cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow the disease. The study was terminated early, so the full result…
Phase 2 • Sponsor: Allarity Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC